List of Excipients in Branded Drug GALANTAMINE HYDROBROMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CELLULOSE, MICROCRYSTALLINE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	CROSPOVIDONE
Patriot Pharmaceuticals LLC	GALANTAMINE HYDROBROMIDE	galantamine hydrobromide	10147-0881	FERRIC OXIDE YELLOW

Generic Drugs Containing GALANTAMINE HYDROBROMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc.	galantamine hydrobromide	0054-0137	METHYLPARABEN
Hikma Pharmaceuticals USA Inc.	galantamine hydrobromide	0054-0137	PROPYLPARABEN
Hikma Pharmaceuticals USA Inc.	galantamine hydrobromide	0054-0137	SACCHARIN SODIUM

What are the Most Frequently-Used Excipients in GALANTAMINE HYDROBROMIDE?

# Of NDCs	Excipient
2	FD&C YELLOW NO. 6
5	FERRIC OXIDE RED
2	FERRIC OXIDE YELLOW

Excipient Strategy and Commercial Opportunities for Galantamine Hydrobromide

Last updated: February 25, 2026

What is the current excipient approach for galantamine hydrobromide?

Galantamine hydrobromide is an acetylcholinesterase inhibitor used primarily for Alzheimer's disease. It is available in immediate-release capsules and tablets. Common excipients include microcrystalline cellulose, lactose monohydrate, sodium starch glycolate, magnesium stearate, and colloidal silicon dioxide. For liquid formulations, binders like methylcellulose and preservatives such as benzyl alcohol are used.

Standard excipient formulations:

• Capsules: Microcrystalline cellulose, lactose, sodium starch glycolate, magnesium stearate
• Tablets: Similar excipients with compression aids
• Liquid formulations: Methylcellulose, preservatives, flavoring agents

How can excipient selection optimize drug delivery?

Excipient selection influences bioavailability, stability, manufacturability, and patient adherence. For galantamine, optimizing excipients involves balancing release profiles, minimizing excipient-related side effects, and ensuring stability.

Opportunities include:

• Controlled-release matrices: Using polymers such as hydroxypropyl methylcellulose (HPMC) or ethylcellulose can extend release, reducing dosing frequency.
• Taste masking: Incorporating flavoring agents and solubilizers teicine bitterness.
• Stability enhancement: Selecting excipients that prevent moisture ingress or oxidation, such as desiccants and antioxidants.
• Formulation flexibility: Adopting transparent, low-viscosity carriers for liquid formulations.

What are the commercial opportunities related to excipients?

The growth of generic versions and value-added formulations opens markets for innovative excipient strategies.

Market dynamics:

• The global galantamine market was valued at USD 170 million in 2022, with a compound annual growth rate (CAGR) of 4% projected through 2030.[1]
• The trend toward once-daily controlled-release formulations enhances market share, driven by convenience and adherence.
• Industry innovations in excipients, such as osmotic delivery systems and bioadhesive matrices, enable differentiation and patenting.

Opportunities include:

• Developing proprietary controlled-release systems using unique polymers.
• Creating pediatric or alternative dosage forms with taste masking and appealing excipient profiles.
• Partnering with excipient manufacturers for specialized formulations that improve stability or reduce side effects.

How does excipient innovation compare to other drug development considerations?

While active pharmaceutical ingredient (API) quality remains fundamental, excipient innovation can serve as a differentiator:

Aspect	Impact on Marketability	Regulatory Considerations	Cost Implication
API purity and potency	Critical	Strict	High
Excipient optimization	Enhances patient adherence, stability	Moderate to strict	Moderate
Innovative delivery systems	Competitive advantage	Often requires additional data	Higher initial investment

What are regulatory trends concerning excipients?

Regulators like the FDA and EMA require comprehensive safety data for excipients, especially for new or proprietary excipients. Clear documentation on excipient sourcing, impurity profiles, and batch consistency is mandatory. Recent updates encourage the use of well-characterized excipients with established safety profiles, while approving novel excipients if safety and efficacy are demonstrated.

Strategic considerations for excipient development

• Evaluate current formulations for bioequivalence with existing brands.
• Invest in excipient screening to identify polymers that modify release or stability.
• Assess supply chain stability and regulatory status of novel excipients.
• Consider intellectual property rights related to excipient combinations or delivery systems.

Key Market Trends

• Growing preference for once-daily, controlled-release tablets enhances demand for specialized excipients.
• Increased focus on patient compliance, especially in elderly populations, favors taste-masked and easy-to-swallow formulations.
• Rise of biosimilars and generics underscores value in excipient innovation as a differentiation point.

Key Takeaways

• Excipients impact bioavailability, stability, and patient adherence, making their selection strategic in galantamine formulation.
• Controlled-release and taste-masked formulations create commercial differentiation and revenue streams.
• Innovations in excipients, such as bioadhesives and specialized polymers, support patentability and market expansion.
• Regulatory compliance drives the adoption of well-characterized excipients with documented safety profiles.
• Strategic partnerships with excipient suppliers can reduce costs and accelerate time-to-market.

FAQs

1. Are there opportunities for patenting excipient-based formulations of galantamine?
Yes. Controlled-release matrix systems, taste-masking techniques, and novel excipient combinations can be patented.

2. What are the main challenges in developing excipient-based formulations?
Ensuring excipient stability, regulatory approval, compatibility with active ingredients, and scalability.

3. How does excipient choice influence the bioavailability of galantamine?
Excipient properties affect dissolution rate, formulation pH, and release profile, directly impacting bioavailability.

4. Can excipient innovation extend patent life for galantamine products?
Yes. New formulations with novel excipients can be patented, extending market exclusivity.

5. What market segments benefit most from excipient innovation in galantamine?
Elderly patients requiring compliance-friendly formulations; markets focusing on controlled-release and pediatric products.

References

[1] Grand View Research. (2023). Galantamine Market Size, Share & Trends Analysis Report.